(1)A substance shall be added to schedule
IV by the general assembly when:
(a)The substance has a low potential for abuse relative to substances
included in schedule III;
(b)The substance has currently accepted medical use in treatment in the
United States; and
(c)The abuse of the substance may lead to limited physical dependence or
psychological dependence relative to the substances included in schedule III.
(2)Unless specifically excepted by Colorado or federal law or Colorado or
federal regulation or more specifically included in another schedule, the following
controlled substances are listed in schedule IV:
(a)Any material, compound, mixture, isomers or salts or isomers, or
preparation containing any of the following narcotic drugs, or their salts calculated
as the
Free access — add to your briefcase to read the full text and ask questions with AI
(1) A substance shall be added to schedule
IV by the general assembly when:
(a) The substance has a low potential for abuse relative to substances
included in schedule III;
(b) The substance has currently accepted medical use in treatment in the
United States; and
(c) The abuse of the substance may lead to limited physical dependence or
psychological dependence relative to the substances included in schedule III.
(2) Unless specifically excepted by Colorado or federal law or Colorado or
federal regulation or more specifically included in another schedule, the following
controlled substances are listed in schedule IV:
(a) Any material, compound, mixture, isomers or salts or isomers, or
preparation containing any of the following narcotic drugs, or their salts calculated
as the free anhydrous base or alkaloid, in limited quantities as follows:
(I) Not more than 1 milligram of difenoxin and not less than 25 micrograms of
atropine sulfate per dosage unit;
(II) Propoxyphene (dosage forms);
(III) Butorphanol;
(b) Any material, compound, mixture, or preparation containing any quantity
of the following substances having a depressant effect on the central nervous
system, including any salts, isomers, and salts of isomers of them that are
theoretically possible within the specific chemical designation:
(I) Alprazolam;
(II) Barbital;
(III) Bromazepam;
(IV) Camazepam;
(V) Chloral betaine;
(VI) Chloral hydrate;
(VII) Chlordiazepoxide;
(VIII) Clobazam;
(IX) Clonazepam;
(X) Clorazepate;
(XI) Clotiazepam;
(XII) Cloxazolam;
(XIII) Delorazepam;
(XIV) Diazepam;
(XV) Estazolam;
(XVI) Ethchlorvynol;
(XVII) Ethinamate;
(XVIII) Ethyl loflazepate;
(XIX) Fludiazepam;
(XX) Flunitrazepam;
(XXI) Flurazepam;
(XXII) Halazepam;
(XXIII) Haloxazolam;
(XXIV) Ketazolam;
(XXV) Loprazolam;
(XXVI) Lorazepam;
(XXVII) Lormetazepam;
(XXVIII) Mebutamate;
(XXIX) Medazepam;
(XXX) Meprobamate;
(XXXI) Methohexital;
(XXXII) Methylphenobarbital (mephobarbital);
(XXXIII) Midazolam;
(XXXIV) Nimetazepam;
(XXXV) Nitrazepam;
(XXXVI) Nordiazepam;
(XXXVII) Oxazepam;
(XXXVIII) Oxazolam;
(XXXIX) Paraldehyde;
(XL) Petrichloral;
(XLI) Phenobarbital;
(XLII) Pinazepam;
(XLIII) Prazepam;
(XLIV) Quazepam;
(XLV) Temazepam;
(XLVI) Tetrazepam;
(XLVII) Triazolam;
(XLVIII) Zolpidem;
(c) (I) Any material, compound, mixture, or preparation containing any
quantity of the following substance, including any salts, isomers of it that are
theoretically possible: Fenfluramine.
(II) This paragraph (c) is repealed upon removal of fenfluramine and its salts
and isomers from schedule IV of the federal Controlled Substances Act (21 U.S.C.
sec. 812; 21 CFR 1308.14).
(d) Any material, compound, mixture, or preparation containing any quantity
of the following substances having a stimulant effect on the central nervous
system, including their salts, isomers, and salts of isomers:
(I) Cathine;
(II) Diethylpropion;
(III) Fencamfamin;
(IV) Fenpropore;
(V) Mazindol;
(VI) Pemoline (including organometallic complexes and chelates thereof);
(VII) Phentermine;
(VIII) Pipradrol;
(IX) SPA ((-)-1-dimethylamino-1,2-diphenylethane);
(e) Any material, compound, mixture, or preparation containing any quantity
of the following substances, including their salts and isomers:
(I) Modafinil;
(II) Pentazocine;
(III) Sibutramine;
(IV) Stadol (butorphanol tartrate);
(f) Zaleplon.
(3) The board may exempt by rule any compound, mixture, or preparation
containing any depressant substance listed in paragraph (b) of subsection (2) of this
section from the application of all or any part of this article if the compound,
mixture, or preparation contains one or more active medicinal ingredients not
having a depressant effect on the central nervous system, and if the admixtures are
in combinations, quantity, proportion, or concentration that vitiate the potential for
abuse of the substances having a depressant effect on the central nervous system.